Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 7/20 | 1.00 |
| ▸ | PGR | P06401 | 4/20 | 0.78 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.78 |
| ▸ | HRH1 | P35367 | 1/20 | 0.78 |
| ▸ | SERPINA6 | P08185 | 3/20 | 0.76 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.73 |
| ▸ | AR | P10275 | 3/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.68 |
| ▸ | FNTA | P49354 | 1/20 | 0.68 |
| ▸ | FNTB | P49356 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 2/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.58 |
| ▸ | SHBG | P04278 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fludrocortisone SCHEMBL13026141 | 1.00 | NR3C1 (1.00) | NR3C1PGRHIF1AHRH1SERPINA6 | |
| Fludrocortisone SCHEMBL4545 | 1.00 | NR3C1 (1.00) | NR3C1PGRHIF1AHRH1SERPINA6 | |
| Fludrocortisone SCHEMBL19327146 | 1.00 | NR3C1 (1.00) | NR3C1PGRHIF1AHRH1SERPINA6 | |
| Fludrocortisone SCHEMBL4323075 | 1.00 | NR3C1 (1.00) | NR3C1PGRHIF1AHRH1SERPINA6 | |
| Fludrocortisone SCHEMBL10598529 | 1.00 | NR3C1 (1.00) | NR3C1PGRHIF1AHRH1SERPINA6 | |
| Fludrocortisone SCHEMBL23975175 | 1.00 | NR3C1 (1.00) | NR3C1PGRHIF1AHRH1SERPINA6 | |
| Fludrocortisone SCHEMBL14373312 | 1.00 | NR3C1 (1.00) | NR3C1PGRHIF1AHRH1SERPINA6 | |
| Fludrocortisone SCHEMBL21297043 | 0.98 | NR3C1 (0.96) | NR3C1PGRHIF1AHRH1SERPINA6 | |
| SCHEMBL8735123 | 0.93 | NR3C1 (0.87) | NR3C1PGRHIF1AHRH1SERPINA6 | |
| SCHEMBL8735124 | 0.93 | NR3C1 (0.87) | NR3C1PGRHIF1AHRH1SERPINA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1448202-A1 | COMBINATION OF A PDE4 OR PDE3/4 INHIBITOR AND AN ANTI-RHEUMATIC DRUG | ALTANA Pharma AG (DE) | 2004-08-25 | — | — | EP | claimed |
| WO-2003039552-A1 | COMBINATION OF PDE4 OR PDE3/4 INHIBITOR AND AN ANTI-RHEUMATIC DRUG | ALTANA PHARMA AG (DE) | 2003-05-15 | — | — | WO | claimed |
| US-20030092706-A1 | Combination | NYCOMED GMBH (DE) | 2003-05-15 | — | — | US | claimed |
| US-20250179130-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | ON TARGET THERAPEUTICS LLC | 2025-06-05 | — | — | US | disclosed |
| US-12060397-B2 | Soluble lipidated ligand agents for treating eye inflammation | TUFTS MEDICAL CENTER (US) | 2024-08-13 | — | — | US | disclosed |
| CN-116615210-A | Novel anuclear cells as a source for the treatment of platelet-rich plasma-dependent disorders | 血小板生源说股份有限公司 | 2023-08-18 | — | — | CN | disclosed |
| US-20220135633-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | ON TARGET THERAPEUTICS LLC | 2022-05-05 | — | — | US | disclosed |
| US-10233219-B2 | Methods and systems for designing and/or characterizing soluble lipidated ligand agents | TUFTS MEDICAL CENTER (US) | 2019-03-19 | — | — | US | disclosed |
| US-20160052982-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | ON TARGET THERAPEUTICS LLC | 2016-02-25 | — | — | US | disclosed |
| US-20070270441-A1 | Combination | ALTANA PHARMA AG (DE) | 2007-11-22 | — | — | US | disclosed |
| EP-1448202-A1 | COMBINATION OF A PDE4 OR PDE3/4 INHIBITOR AND AN ANTI-RHEUMATIC DRUG | ALTANA Pharma AG (DE) | 2004-08-25 | — | — | EP | disclosed |
| EP-0696598-B1 | Polysaccharide esters and their salts | FIDIA FARMACEUTICI (IT) | 2002-11-13 | — | — | EP | disclosed |
| WO-2002044344-A2 | BASAL CELL CARCINOMA CULTURES, METHODS RELATED THERETO AND THEIR USE | CURIS, INC. (US) | 2002-06-06 | — | — | WO | disclosed |
| WO-2001041746-A1 | ANTI ITCH PATCH | LECTEC CORPORATION (US) | 2001-06-14 | — | — | WO | disclosed |
| EP-0696598-A1 | Polysaccharide esters and their salts | FIDIA S.p.A. (IT) | 1996-02-14 | — | — | EP | disclosed |
| US-5336767-A | Used in cosmetics, surgery or medicine | FIDIA, S.P.A. (IT) | 1994-08-09 | — | — | US | disclosed |
| US-5202431-A | Salified with therapeutically active amine; cosmetics, drugs | FIDIA, S.P.A. (IT) | 1993-04-13 | — | — | US | disclosed |
| US-4965353-A | ESTERS OF HYALURONIC ACID; MICROCAPSULES | FIDIA S.P.A. (IT) | 1990-10-23 | — | — | US | disclosed |
| EP-0216453-A2 | Esters of hyaluronic acid and their salts. | FIDIA S.p.A. (IT) | 1987-04-01 | — | — | EP | disclosed |
| US-4052422-A | ANTIINFLAMMATORY | E. R. SQUIBB & SONS, INC. (US) | 1977-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220135633-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | LDLR, HDLBP, LIPG | NR3C1 3463/4885PGR 1663/4885HIF1A 2861/4885 |
| US-20160052982-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | LDLR, HDLBP, LIPG | NR3C1 3463/4885PGR 1663/4885HIF1A 2861/4885 |
| US-10233219-B2 | Methods and systems for designing and/or characterizing soluble lipidated ligand agents | LDLR, HDLBP, LIPG | NR3C1 3463/4885PGR 1663/4885HIF1A 2861/4885 |
| US-20250179130-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | LDLR, HDLBP, LIPG | NR3C1 3463/4885PGR 1663/4885HIF1A 2861/4885 |
| US-12060397-B2 | Soluble lipidated ligand agents for treating eye inflammation | LIPG, CD40, LDLR | NR3C1 1376/4885PGR 1656/4885HIF1A 1311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.